106 related articles for article (PubMed ID: 7977170)
1. 5-Fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors.
Khansur T; Allred C; Tavassoli M
Am J Clin Oncol; 1994 Dec; 17(6):506-8. PubMed ID: 7977170
[TBL] [Abstract][Full Text] [Related]
2. Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
Karlin DA; Stroehlein JR; Bennetts RW; Jones RD; Heifetz LJ; Mahal PS
Cancer Treat Rep; 1982 Aug; 66(8):1613-7. PubMed ID: 7105051
[TBL] [Abstract][Full Text] [Related]
3. [5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland].
Inoue K; Horikoshi N; Mukaiyama T; Ogawa M; Kuraishi Y
Gan No Rinsho; 1989 Mar; 35(4):481-5. PubMed ID: 2654442
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy in metastatic tumors of unknown origin. 5-Fluorouracil, adriamycin and mitomycin C for adenocarcinomas and adriamycin, vinblastine and mitomycin C for anaplastic carcinomas.
Sulkes A; Uziely B; Isacson R; Brufman G; Biran S
Isr J Med Sci; 1988; 24(9-10):604-10. PubMed ID: 3204009
[TBL] [Abstract][Full Text] [Related]
5. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
Gibson MK; Holcroft CA; Kvols LK; Haller D
Oncologist; 2005 Feb; 10(2):132-7. PubMed ID: 15709215
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of 5-fluorouracil, adriamycin and mitomycin-C in adenocarcinoma of the oesophagus.
Walker SJ; Allen SM; Steel A; Cullen MH; Matthews HR
Clin Oncol (R Coll Radiol); 1991 Nov; 3(6):318-22. PubMed ID: 1742230
[TBL] [Abstract][Full Text] [Related]
8. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.
Goldberg RM; Smith FP; Ueno W; Ahlgren JD; Schein PS
J Clin Oncol; 1986 Mar; 4(3):395-9. PubMed ID: 3754004
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program Trial.
Vaughn DJ; Meropol NJ; Holroyde C; Mintzer D; Nuamah I; Armstead B; Douglass HO; Haller DG
Am J Clin Oncol; 1997 Jun; 20(3):242-6. PubMed ID: 9167745
[TBL] [Abstract][Full Text] [Related]
10. 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) in the treatment of inoperable adenocarcinoma of the lung.
Shepherd FA; Evans WK; Burkes R; Paul K; DeBoer G
Am J Clin Oncol; 1986 Oct; 9(5):392-6. PubMed ID: 3776901
[TBL] [Abstract][Full Text] [Related]
11. 5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
van der Gaast A; Verweij J; Planting AS; Stoter G
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):765-8. PubMed ID: 3383976
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary.
Treat J; Falchuk SC; Tremblay C; Spielman M; Woolley PV; Rouesse J; Sevin D; Le Chevalier T
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1053-5. PubMed ID: 2759160
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma.
Li J; Yao X; Kortmansky JS; Fischbach NA; Stein S; Deng Y; Zhang Y; Doddamane I; Karimeddini D; Hochster HS; Lacy J
Am J Clin Oncol; 2017 Apr; 40(2):146-151. PubMed ID: 25144267
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
15. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Walsh G; Komaki R; Morris J; Swisher SG; Putnam JB; Lynch PM; Wu TT; Smythe R; Vaporciyan A; Faust J; Cohen DS; Nivers R; Roth JA
Cancer; 2004 Jun; 100(11):2347-54. PubMed ID: 15160337
[TBL] [Abstract][Full Text] [Related]
16. O-MAX chemotherapy: high activity in metastatic esophagogastric adenocarcinoma and possible relation to subclinical hemolysis.
Ahlgren J; Patel N; Simmens S; Akin E; Bishop C; Kirkel D; Siegel P; Schuck S; Guebre-Xabiher H; Siegel R
Oncology; 2014; 87(6):371-80. PubMed ID: 25227924
[TBL] [Abstract][Full Text] [Related]
17. Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (modified FAM).
Haim N; Epelbaum R; Cohen Y; Robinson E
Cancer; 1984 Nov; 54(9):1999-2002. PubMed ID: 6548173
[TBL] [Abstract][Full Text] [Related]
18. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
Kim SY; Park HC; Yoon C; Yoon HJ; Choi YM; Cho KS
Cancer; 1998 Nov; 83(10):2054-9. PubMed ID: 9827708
[TBL] [Abstract][Full Text] [Related]
19. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Roth JA; Ryan MB; Putnam JB; Pazdur R; Levin B; Gutterman JU; McMurtrey M
J Clin Oncol; 1993 Jan; 11(1):22-8. PubMed ID: 8418237
[TBL] [Abstract][Full Text] [Related]
20. Adenocarcinoma of the esophagus and gastroesophageal junction. Clinical and pathologic assessment of response to induction chemotherapy.
Adelstein DJ; Rice TW; Boyce GA; Sivak MV; Van Kirk MA; Kirby TJ; van Stolk RU; Bukowski RM
Am J Clin Oncol; 1994 Feb; 17(1):14-8. PubMed ID: 8311001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
